Quality of Life Among Survivors of Hodgkin Lymphoma

This study is currently recruiting participants.

Verified by Memorial Sloan-Kettering Cancer Center, January 2009

First Received: January 10, 2008 Last Updated: January 8, 2009 History of Changes

Sponsored by:	Memorial Sloan-Kettering Cancer Center
Information provided by:	Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:	NCT00598728

Purpose

The purpose of this study is to collect information on the long-term side effects of treatment for Hodgkin Lymphoma. We hope to study about 500-800 survivors of Hodgkin Lymphoma. We plan to use the findings from this study to better understand Hodgkin Lymphoma survivors' health and quality of life.

Condition	Intervention
Hodgkin's Disease	Behavioral: Quality of Life Questionaires

MedlinePlus related topics: Cancer Hodgkin's Disease Lymphoma

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Retrospective
Official Title:	A Global Assessment of Medical Morbidities and Quality of Life Among Survivors of Hodgkin Lymphoma

Further study details as provided by Memorial Sloan-Kettering Cancer Center:

Primary Outcome Measures:

To evaluate the prevalence of late medical complications among HL survivors [ Time Frame: conclusion of study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

To study the effect of HL and its treatment on QOL among HL survivors. [ Time Frame: conclusion of study ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	500
Study Start Date:	May 2005
Estimated Study Completion Date:	May 2010
Estimated Primary Completion Date:	May 2010 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
1 Hodgkin lymphoma Survivors	Behavioral: Quality of Life Questionaires A patient questionnaire, which includes questions on medical morbidities and QOL, will be mailed to participants.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

The study population will be recruited from over 800 patients who were enrolled on IRB approved protocols for the firstline treatment of HL between 1975-2000.

Criteria

Inclusion Criteria:

Biopsy-proven HL Participation in IRB-approved protocols for the first-line treatment of HL between 1975-2000 (IRB #75-104, #75-103, #79-17, #81-103, #90-44, #91-69).
English speaking

Exclusion Criteria:

None

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00598728

Contacts

Contact: David Straus, MD		strausd@mskcc.org
Contact: Jennifer Ford, PhD		fordj@mskcc.org

Locations

United States, New York
Memorial Sloan-Kettering Cancer Center	Recruiting
New York, New York, United States, 10065
Contact: David Straus, MD strausd@mskcc.org
Contact: Jennifer Ford, PhD fordj@mskcc.org
Principal Investigator: David Straus, MD

Sponsors and Collaborators

Memorial Sloan-Kettering Cancer Center

Investigators

Principal Investigator:

David Straus, MD

Memorial Sloan-Kettering Cancer Center

More Information

Additional Information:

Memorial Sloan-Kettering Cancer Center This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Memorial Sloan Kettering Cancer Center ( David Straus, MD )
Study ID Numbers:	05-041
Study First Received:	January 10, 2008
Last Updated:	January 8, 2009
ClinicalTrials.gov Identifier:	NCT00598728 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by Memorial Sloan-Kettering Cancer Center:

Survivors
Quality of Life

Study placed in the following topic categories:

Lymphatic Diseases
Immunoproliferative Disorders
Hodgkin Lymphoma, Adult
Hodgkin's Disease

Quality of Life
Lymphoproliferative Disorders
Hodgkin Disease
Lymphoma

Additional relevant MeSH terms:

Lymphatic Diseases
Neoplasms
Immunoproliferative Disorders
Neoplasms by Histologic Type

Immune System Diseases
Lymphoproliferative Disorders
Lymphoma
Hodgkin Disease

ClinicalTrials.gov processed this record on May 07, 2009